Premium
Effects of varenicline, nicotine or placebo on depressive symptoms in postmenopausal smokers
Author(s) -
Avery Naomi,
Kenny Anne M.,
Kleppinger Alison,
Brindisi Jennifer,
Litt Mark D.,
Oncken Cheryl A.
Publication year - 2014
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1111/j.1521-0391.2014.12130.x
Subject(s) - varenicline , major depressive disorder , smoking cessation , medicine , depression (economics) , placebo , nicotine , population , psychiatry , history of depression , mood , anxiety , alternative medicine , environmental health , pathology , economics , macroeconomics
Background Varenicline carries a black box warning for neuropsychiatric adverse events. Objective We examined varenicline use and past history of major depressive disorder (MDD) on depressive symptoms during smoking cessation. Method This is a secondary analysis of two smoking cessation studies in 152 postmenopausal women who received placebo or nicotine patch, or 78 women who received varenicline with relaxation. Lifetime history of MDD (LH‐MDD) was assessed at baseline and women with current MDD were excluded. Center for Epidemiologic Study Depression scale (CESD) measured depressive symptoms at baseline, 6 and 12 weeks. Results Baseline CESD scores were 5.3 + 4.4. Those with a LH‐MDD reported higher CESD scores ( p > .001). Those taking varenicline reported lower scores over all time periods compared to nicotine or placebo ( p < .01). The differences between varenicline and the other treatments remained when controlling for LH‐MDD, indicating an independent effect. CESD scores were associated with concurrent smoking status ( p < .001), and with withdrawal symptoms ( p < .001). Conclusion CESD score were lower in those receiving varenicline, whether this is due to an anti‐depressant effect, subject selection, use of relaxation or another cause is unknown. Varenicline does not increase depressive symptoms during smoking cessation in postmenopausal women without current MDD. Subjects with a LH‐MDD are susceptible to developing depressive symptoms during smoking cessation, regardless of pharmacologic aid. Scientific Significance Pharmacologic aids did not increase depression symptoms in this select population of postmenopausal women without current depression. Smoking cessation does increase depressive symptoms in those with LH‐MDD, though the degree of increase was not clinically meaningful. (Am J Addict 2014;23:459–465)